Connect to other sites within the UBM Medica Network
Four questions for you to answer, four facts you need to know.
Have You Heard This (Week's) News?
Microbes in the gut affect metabolic pathways involved in the pathogenesis of obesity, insulin resistance, and diabetes. Antibiotics can alter gut microbiota.
Aflibercept (Eylea, Regeneron Pharmaceuticals), a second ophthalmic vascular endothelial growth factor inhibitor, has received FDA approval for the treatment of diabetic retinopathy in patients with diabetic macular edema.
Poor GLP-1 Response Seen Before Type 2 Diabetes Develops
A Danish study found reduced endogenous levels of glucagon-like peptide-1 in persons with prediabetes. Perhaps the incretin system defect comes first.
Comorbid Curiousity: Which One Doesn't Pertain?
Conditions associated with long-term diabetes affect myriad organs and systems. Which one of these comorbidities is not associated with the disease?
Diabetes Pop Quiz: Esophageal Ups and Downs
What are some of the esophageal complications seen in patients with long-standing hyperglycemia?
GLP-1RAs Good for Diabetes, Good for the Heart
Glucagon-like peptide-1 receptor agonists represent a novel class of antihyperglycemic agents that have a cardiac-friendly profile.
Diabetes Complications Vary Little by Ethnicity
Examining ethnic patterns of prevalent geriatric conditions in diabetes may help ensure culturally competent, patient-centered care in an increasingly diverse population.
Five Top Papers From 2014 That Will Impact Your Practice
New drugs that treat stubborn illness seen often in primary care lead this group of Top 5 Papers for 2014. Type 2 diabetes, cryptogenic stroke, and hep-C are key targets.
By clicking Accept, you agree to become a member of the UBM Medica Community.